ArticleMolecular biology reports2026
Cardiac drug potential: exploring individual and combined cardiac drugs to promote differentiation of adipose-derived stem cells into cardiomyocytes.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStem cell–based cardiac regenerative medicine holds significant promise for regenerating damaged cardiomyocyte by cardiomyocyte differentiation. Among stem cell types, adipose-derived stem cells (ADSCs) are the most extensively studied due to their ease of isolation and expansion, yet current differentiation protocols remain inefficient and poorly reproducible. Given the well-established roles of certain cardiac drugs—such as Salbutamol, Ivabradine, and Entresto—their potential influence on the regulation of cardiomyocyte differentiation may provide a valuable foundation for advancing differentiation protocols. This study investigates the potential of clinically approved cardiac drugs to enhance ADSC differentiation into cardiomyocytes.
methodsADSCs were isolated from adipose tissue after liposuction surgery from healthy female patients (n = 6, age 23–40 year) using enzymatic methods. ADSCs at early passages (2–3) were treated with Salbutamol, Ivabradine, or Entresto for 21 days. Subsequently, RT-PCR was performed for pluripotency markers (OCT4, NANOG, and SOX2) and cardiac-specific genes (GATA4, NKX2.5, cTNNI, α-MHC).
resultTreatment of ADSCs with each cardiac drug independently led to downregulation of pluripotency-markers compared to controls which indicate a loss of stemness. This was accompanied by increased expression of some early cardiomyocyte markers and slight increase in late cardiomyocyte markers expression, indicating commitment toward cardiac lineage commitment. In light of these results, a combination of these drugs have improved the differentiation of ADSCs into cardiomyocytes and significantly increase gene expression of early cardiomyocyte markers and late cardiomyocyte markers.
conclusionClinically approved cardiac drugs promote ADSC differentiation toward the cardiomyocyte lineage, offering a novel and safe approach for cardiac regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.